TREVI THERAPEUTICS
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
TREVI THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Sandy Hook, Connecticut, United States
Country:
United States
Website Url:
http://www.trevitherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
203-304-2499
Email Addresses:
[email protected]
Total Funding:
156.53 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fairmount Funds Management
Fairmount Funds Management investment in Post-IPO Equity - Trevi Therapeutics
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Trevi Therapeutics
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - Trevi Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Trevi Therapeutics
Omega Funds
Omega Funds investment in Series C - Trevi Therapeutics
TPG Biotech
TPG Biotech investment in Series C - Trevi Therapeutics
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Trevi Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series C - Trevi Therapeutics
TPG Biotech
TPG Biotech investment in Series C - Trevi Therapeutics
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Trevi Therapeutics
Official Site Inspections
http://www.trevitherapeutics.com Semrush global rank: 7.6 M Semrush visits lastest month: 455
- Host name: cloudproxy10117.sucuri.net
- IP address: 192.124.249.117
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
